9 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Chronic Disease
  • Digestive System Disorder
  • Therapy
  • Vaccine

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Digestive System Disorder
  • Vaccine

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Digestive System Disorder
  • Vaccine

About ## percent of people who have food allergies are allergic to more than one food.

  • Allergy
  • Chronic Disease
  • Pharmaceutical
  • Therapy
  • Vaccine

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Allergy
  • Vaccine
  • Japan
  • World
  • Product Initiative

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • Vaccine

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Antibiotic Resistance
  • Cell Therapy
  • Digestive System Disorder
  • Vaccine
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Digestive System Disorder
  • Vaccine
  • United States
  • Product Initiative

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antibiotic Resistance
  • Antifungal
  • Digestive System Disorder
  • Infectious Disease
  • Vaccine